Is TriSalus Life Sciences, Inc. (TLSIW) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| DJIM | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| MSCI | 98.6% / 33% | 35.6% / 33% | 21.2% / 33% | 1.37% / 5% | ✗ NOT HALAL |
| S&P | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| FTSE | 98.6% / 33% | 35.6% / 33% | 21.2% / 50% | 1.37% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 84.6% | |
| Operating Margin | -24.8% | |
| Net Margin | -86.9% | |
| Return on Assets (ROA) | -56.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$18M |
| Free Cash Flow | -$19M |
| Total Debt | $34M |
| Current Ratio | 2.8 |
| Total Assets | $35M |
Price & Trading
| Last Close | $1.02 |
| 50-Day MA | $1.36 |
| 200-Day MA | $1.47 |
| Avg Volume | 3K |
| Beta | 0.4 |
|
52-Week Range
$0.42
| |
About TriSalus Life Sciences, Inc. (TLSIW)
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Related Halal Stocks in
Frequently Asked Questions
Is TriSalus Life Sciences, Inc. (TLSIW) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), TriSalus Life Sciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is TriSalus Life Sciences, Inc.'s debt ratio?
TriSalus Life Sciences, Inc.'s debt ratio is not available under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 98.6%.
What are TriSalus Life Sciences, Inc.'s key financial metrics?
TriSalus Life Sciences, Inc. has a market capitalization of N/A, and revenue of $45M. The company maintains a gross margin of 84.6% and a net margin of -86.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.